Product Information
FEBUXOSTAT 80 MG TABLET is a generic product labeled by Macleods Pharmaceuticals Limited, priced at $0.2610 per EA under NDC 33342027507. Its NADAC has been published 127 times since May 1, 2024.
FDA first approved this application on Sep 28, 2023. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
80 mg/1
Manufacturer
Macleods Pharmaceuticals LimitedNDC
33342027507
Classification
Generic
Dosage Form
FILM
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
FEBUXOSTATApproval Type
Generic (ANDA)
FDA Application
ANDA207293FDA Approved
9/28/2023
TE Code
AB
On Market Since
4/4/2019
Pharmacological Classes
Price Statistics
The NADAC for FEBUXOSTAT 80 MG TABLET has been published 127 times since May 1, 2024, and over the history we have for it it has declined 31.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.2610 per EA |
|---|---|
| All-time high | $0.5895 (Nov 13, 2024) |
| All-time low | $0.2610 (Sep 23, 2026) |
| 52-week high | $0.3536 |
| 52-week low | $0.2610 |
| Median price | $0.4107 |
| Average price | $0.4038 |
| Largest weekly change | +30.2% (Aug 21, 2024) |
| Weeks tracked | 127 |
| Tracking since | May 1, 2024 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Febuxostat tablets 80 mg market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Macleods Pharmaceuticals Limited manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Febuxostat tablets 80 mg market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Xanthine Oxidase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of FEBUXOSTAT 80 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for FEBUXOSTAT 80 MG TABLET, manufactured by Macleods Pharmaceuticals Limited, is $0.2610 per EA (NDC 33342027507), effective Sep 30, 2026.
How has the price of FEBUXOSTAT 80 MG TABLET changed over time?
Over the history we have for it, the NADAC for FEBUXOSTAT 80 MG TABLET has declined 31.1%. It has been tracked across 127 weekly CMS publications since May 1, 2024.
What are the highest and lowest recorded NADAC prices for FEBUXOSTAT 80 MG TABLET?
Since May 1, 2024, the NADAC for FEBUXOSTAT 80 MG TABLET has ranged from a low of $0.2610 (Sep 23, 2026) to a high of $0.5895 (Nov 13, 2024), with a median of $0.4107 per EA.
Are there cheaper alternatives to FEBUXOSTAT 80 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of FEBUXOSTAT 80 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures FEBUXOSTAT 80 MG TABLET?
FEBUXOSTAT 80 MG TABLET (NDC 33342027507) is labeled by Macleods Pharmaceuticals Limited, and CMS classifies it as a generic product.